Proactive Investors - Run By Investors For Investors

e-Therapeutics and C4X Discovery to collaborate on Parkinson's Disease treatment

The collaboration will see e-Therapeutics combine its Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology
doctor
Parkinson's affects 10mln people worldwide

e-Therapeutics PLC (LON:ETX) and C4X Discovery Holdings PLC (LON:C4X) are to pool their knowledge to try to find a treatment for Parkinson’s Disease.

The collaboration will see e-Therapeutics combine its Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology, which utilises genomes to identify new patient-specific targets, the company said in a statement.

READ: One year on, new boss is spearheading turnaround at drug discovery firm e-therapeutics

Parkinson's Disease is a degenerative disorder of the central nervous system estimated to affect 10 million people worldwide.

No cure is available currently and the aim of the collaboration is to identify new treatment strategies, molecular targets and, ultimately, novel drugs.

Taxonomy3 has already identified 180 novel disease-associated genes for Parkinson’s and e-therapeutics will use its NDD platform to help understand how the cellular mechanisms interact in the pathology of the disease.

Ray Barlow, e-therapeutics’ chief executive, said there remains a significant unmet medical need for truly effective treatments for Parkinson’s Disease.

"Our aim is to use the genomic associations that C4XD's Taxonomy3 technology platform has uncovered, to create new therapeutic approaches to treat this devastating disease."

He added the group is also working on genome-based functionality for its NDD platform in other areas including triple negative breast cancer.

The financial terms of the agreement were not disclosed.

View full ETX profile View Profile

e-Therapeutics plc Timeline

CN Video
March 28 2018

Related Articles

scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use